Non-Small-Cell Lung Cancer
Conditions
Interventions
Weekly nab-Paclitaxel+Carboplatin with Radiotherapy
Sponsors
University of Fukui Faculty of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathological stage IIIA, IIIB stage that is diagnosed as pathologically non-small cell lung cancer and judged to be resectable on the image. 2) Diagnosis of ipsilateral mediastinal lymph node metastasis (N2) is histologically proven (bronchoscopy, mediastinoscopy), or obvious swelling (minor diameter greater than 20 mm) allowed . 3) For T4, a case clearly showing invasion on the image (CT, MRI, PET - CT). 4) Cases with no resistance to chemotherapy or radiotherapy for non-small cell lung cancer 5) ECOG's Performance Status (PS) is 0 to 1. 6) The age is over 20 years old and under 79 years old. 7) Within 14 days prior to enrollment patients have adequate bone marrow, liver, kidney and lung function
Exclusion criteria
Exclusion criteria: 1) Taxane and CBDCA are contraindicated for administration. 2) A history of severe drug sensitivity. 3) A history of hypersensitivity to albumin. 4)Interstitial pneumonia or pulmonary fibrosis apparent in chest radiography. 5) Active or duplicated cancer with metachronous or simultaneous, multiple cancers. 6) Pleural effusion, drainage and pericardial effusion required drainage. 7) Have serious complications. 8) Patients with peripheral neuropathy of Grade 2 or higher. 9) HBs antigen positive 10) Pregnant women or women who may be pregnant. 11) A man who is willing to conceive. 12) The doctor in charge judged unsuitable for registration of this exam.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The complete resection rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 2 years no relapse survival rate and progression free survival rate for 2 years. | — |
Countries
Japan
Contacts
Public ContactMasato Sasaki
University of Fukui Faculty of Medical Sciences Division of Thoracic Surgery, Department of Surgery
Outcome results
None listed